EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Heart Failure with Preserved Ejection Fraction as a Multisystem Syndrome: A Mechanistically Anchored Endotype Framework for Precision Therapy

Beata Krasińska iD, Zbigniew Krasiński iD, Tomasz Urbanowicz iD

Journal of Clinical Medicine · 28.05.2026 · 15 (11) · 4159

DOI: 10.3390/jcm15114159 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.05.2026. Verfasst von Beata Krasińska und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hypertensiology, Angiology, and Internal Medicine, Poznan University of Medical Sciences, 61-701 Poznań, Poland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases worldwide and remains associated with substantial morbidity, mortality, and limited therapeutic efficacy. This persistent therapeutic gap reflects not only clinical heterogeneity but also a fundamental conceptual limitation: HFpEF has been approached as a myocardial disorder despite mounting evidence that it represents a multisystem syndrome. In this perspective, we integrate current pathophysiological and clinical evidence into a mechanistically anchored endotype framework based on dominant biological axes. We propose four overlapping endotypes—cardiorenal, fibrotic–inflammatory, metabolic–adiposity, and microvascular–energetic—and align contemporary and emerging therapies with these domains. We further outline a pragmatic roadmap for biomarker-guided stratification and propose principles for next-generation clinical trial design based on mechanistic enrichment. This framework provides a clinically actionable structure for biomarker-guided stratification and supports mechanism-based therapeutic selection in HFpEF. Aligning dominant biological drivers with targeted interventions generates testable hypotheses for endotype-enriched clinical trials and precision treatment strategies. Prospective validation of this approach may facilitate a transition from uniform management toward individualized, biology-driven care.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistsHFpEFSGLT2 inhibitorsbiomarker-guided therapycardiorenal syndromeendotypesheart failure with preserved ejection fractionmetabolic inflammationmyocardial fibrosisprecision medicine

Autor:innen und Institutionen

  • Department of Hypertensiology, Angiology, and Internal Medicine, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
  • Department of Vascular, Endovascular Surgery, Angiology and Phlebology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
  • Cardiac Surgery and Transplantology Department, Poznan University of Medical Sciences, 61-701 Poznań, Poland.

ORCID-Profile: Beata Krasińska, Zbigniew Krasiński, Tomasz Urbanowicz

Zitieren

APA

Krasińska, B., Krasiński, Z., & Urbanowicz, T. (2026). Heart Failure with Preserved Ejection Fraction as a Multisystem Syndrome: A Mechanistically Anchored Endotype Framework for Precision Therapy. Journal of Clinical Medicine, 15(11), 4159. https://doi.org/10.3390/jcm15114159

Vancouver

Krasińska B, Krasiński Z, Urbanowicz T. Heart Failure with Preserved Ejection Fraction as a Multisystem Syndrome: A Mechanistically Anchored Endotype Framework for Precision Therapy. Journal of Clinical Medicine. 2026;15(11):4159. doi:10.3390/jcm15114159

BibTeX
@article{Krasiska2026,
  author = {Krasińska, Beata and Krasiński, Zbigniew and Urbanowicz, Tomasz},
  title = {Heart Failure with Preserved Ejection Fraction as a Multisystem Syndrome: A Mechanistically Anchored Endotype Framework for Precision Therapy},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {4159},
  doi = {10.3390/jcm15114159}
}
Kostenlos starten →